All Submissions
Real-world outcomes for the safety of SGLT2 Inhibitor luseogliflozin in elderly patients with type 2 diabetes
0 views
0 downloads
Video
PDF
Abstract
0 Datasets
Powered by
Discover more research and events on
morressier.com
Imprint
Terms of Service
Privacy Policy
Accessibility